TipRanks on MSN
vTv Therapeutics initiated with a Buy at BTIG
BTIG initiated coverage of vTv Therapeutics (VTVT) with a Buy rating and $40 price target vTv is a clinical-stage biotech company developing oral drugs for metabolic and inflammatory diseases, the ...
Zacks Investment Research on MSN
All You Need to Know About vTv Therapeutics (VTVT) Rating Upgrade to Buy
Tv Therapeutics (VTVT) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...
Topline Phase 3 CATT1 data for cadisegliatin in type 1 diabetes expected second half 2026 $80 million private placement strengthens balance sheet and supports Phase 3 CATT1 completion Announced issuan ...
Topline Phase 3 CATT1 data for cadisegliatin in type 1 diabetes expected second half 2026 $80 million private placement ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback